Navigation Links
Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
Date:10/30/2008

WALTHAM, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, November 6th, 2008 at 10:00 a.m. EST, to report second quarter fiscal year 2009 financial results and to provide a quarterly update of the Company.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at http://www.repligen.com. If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (866) 825-3209 for domestic calls and (617) 213-8061 for international calls. Participants must provide the following passcode: 62476438. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at http://www.repligen.com.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
2. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
3. Repligen Elects Earl Henry, M.D. to the Board of Directors
4. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
5. Repligen Announces Share Repurchase Program
6. Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... According to an article published May 5th on ... concerned about their breath. In fact, it found that more than a third cited unappealing ... caused temporarily by pungent foods or a failure to brush after meals, can typically be ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Horizon Foundation for New ... initiative to improve oral health-related awareness, education, prevention and treatment for young people. ... and promote best practices in 10 New Jersey counties where dental health needs ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... announces that Lake City Bank has selected IFN as a fiber transport provider. ... resulting in increased efficiencies and reduced costs. , “IFN provides fiber ...
(Date:5/25/2016)... O'Fallon, MO (PRWEB) , ... May 25, 2016 , ... ... located in Woodlawn Plaza at 8618 Mexico Road, O’Fallon, MO 63366. He serves patients ... and cosmetic treatments . Dr. Schwarz’s success is reflected in the superior ...
(Date:5/25/2016)... California (PRWEB) , ... May 25, 2016 , ... ... interest group ADDMI - “Advancing Drug Development through Molecular Imaging.” The focus of ... of the current drug discovery and development pipeline issues. Through ADDMI-IG WMIS will ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today announced ... for wounds and infections. This test ensures discovery ... select viruses. The test requires only a simple swab ... David G. Bostwick , MD, Chief ... facilitate wound healing: "We are excited to make ...
(Date:5/25/2016)... May 25, 2016 ReportsnReports.com ... research report that provides an overview on therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:5/24/2016)... , May 24, 2016   ... demonstrating non-inferiority in overall bowel cleansing and superiority in ... c leansing of the ... ) , Norgine B.V. today announced new positive ... PEG and ascorbate bowel preparation) versus standard 2 litre PEG with ...
Breaking Medicine Technology: